Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind study of subcutaneous RO7790121 in moderate to severe active Crohn’s disease
2023-504265-23-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of afimkibart in Crohn's disease (2 arms), sponsored by Roche. Primary endpoint: Safety (TEAEs, SAEs, AEs leading to discontinuation). Planned start Oct 2023; status: authorised.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-504265-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504265-23-00.